adam brufsky, md, phd, considers the investigation of poziotinib in her2 metastatic breast cancer
Published 3 years ago • 152 plays • Length 3:21Download video MP4
Download video MP3
Similar videos
-
2:39
adam brufsky, md, phd, describes the treatment landscape of her2 metastatic breast cancer
-
1:22
dr. brufsky on trastuzumab and eribulin for her2 metastatic breast cancer
-
0:49
adam brufsky, md, phd: considerations for different therapies in breast cancer
-
1:44
adam brufsky, md, phd: choices of therapy in breast cancer
-
1:49
dr. brufsky on multiparametric genomic assays in breast cancer
-
35:36
md vs md/phd vs phd: steve lee, ph.d. (2014)
-
2:38
aleasa barry - accelerated partial breast irradiation (apbi)
-
10:47
overview of bronchiectasis diagnosis & treatment: dr. alan barker
-
1:07
adam brufsky, md, phd: expectations of therapy in breast cancer
-
1:10
adam brufsky, md, phd: choices of therapy
-
1:01
dr. brufsky on trastuzumab biosimilars in breast cancer
-
1:04
adam brufsky, md, phd: expectations of therapy
-
1:38
dr. brufsky on the results of a study of trastuzumab and eribulin for her2 mbc
-
1:06
dr. brufsky on challenges in breast cancer
-
1:46
dr. brufsky discusses adjuvant bisphosphonates as a new standard of care
-
1:19
dr adam brufsky: choosing a therapy for breast cancer patients
-
5:43
cdk4/6 inhibitors in metastatic disease
-
0:30
dr. brufsky on adjuvant bisphosphonates for patients with breast cancer
-
2:47
adam brufsky, md, phd: clinical trial data supporting these choices
-
4:30
adam brufsky, md, phd, discusses results of monarch-2, paloma-1 trials
-
1:16
dr. brufsky advises doctors on bevacizumab for breast cancer
-
2:12
dr adam brufsky discusses value coordinates of breast cancer care